The study, published in JAMA Neurology, was conducted at three designated special care centers for COVID-19 in a hospital in Wuhan, China.
Researchers examined clinical data for 214 COVID-19 patients collected from Jan. 16 to Feb. 19. Neurologic symptoms fell into three categories: central nervous system manifestations, such as dizziness, headaches and seizures; peripheral nervous system manifestations, such as taste, smell and vision impairment and nerve pain; and skeletal muscle injury.
Of the 214 patients, 78 (36.4 percent) had neurologic symptoms.
Eighty-eight of the 214 patients had a severe case of COVID-19. Patients with severe infections had higher rates of some neurologic symptoms. For example, 14.8 percent with severe infections showed impaired consciousness, compared to 2.4 percent of patients who did not have a severe infection.
Researchers also found that most neurologic symptoms occurred early in the illness.
More articles on infection control:
Shortage of protective gear leads hospitals to buy and keep faulty N95 masks
Policies at Pennsylvania hospitals endangered patients, staff, whistleblowers say
Extended use of N95s is safer than reuse, ECRI suggests
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
